Medical News

RSS

Viewpoints: Celebrating health law anniversary (or not); Tricare's 'modest' fee increase; Funding Planned Parenthood

Since President Barack Obama signed the Affordable Care Act into law a year ago this month, we've heard endless partisan bickering about repeal efforts, legal challenges and fairness. But we've heard little about how the law is already helping secure the future of all Americans (Donna E. Shalala, 3/19).

21 Mar 2011

LTC declares $0.50 per share quarterly dividend on Series F Cumulative Preferred Stock

LTC Properties, Inc. announced today that it had declared the quarterly cash dividend of $0.50 per share on the Company's 8.0% Series F Cumulative Preferred Stock. The dividend is payable on April 15, 2011 to stockholders of record on April 1, 2011.

21 Mar 2011

WaferGen, NuGEN collaborate to develop integrated workflows for gene expression profiling and target enrichment

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, and NuGEN Technologies, Inc., a leader in innovative genomic samples preparation, today announced they will co-develop and co-market simple, seamlessly integrated workflows for gene expression profiling and target enrichment to enable researchers to more easily achieve high-throughput, high-density real-time PCR with small, degraded, and hard-to-replace clinical specimens, such as formalin fixed paraffin embedded tissue (FFPE).

21 Mar 2011

Teleflex retires all of the 2004 senior notes

Teleflex Incorporated announced today that on March 16, 2011 it prepaid the remaining $64.0 million in aggregate principal amount of its 2004 senior notes. This consisted of $26.75 million of 6.66% senior notes due in 2011, $21.75 million of 7.14% senior notes due in 2014, and $15.5 million of 7.46% senior notes due in 2016, which completely retired all of the 2004 senior notes.

21 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Anacor enters $30 million loan agreement

Anacor Pharmaceuticals announced today that it has entered into a loan agreement led by Oxford Finance Corporation and partnered with Horizon Technology Finance Corporation to provide up to $30 million in capital. Anacor used $6.6 million to repay the remaining obligations under its loan agreement with Lighthouse Capital Partners and expects to use the remainder of the capital to fund development activities related to AN2690, AN2728 and AN2898.

21 Mar 2011

NeuroFocus unveils wireless headset to capture brainwave activity across the full brain

NeuroFocus unveiled the first dry, wireless headset designed to capture brainwave activity across the full brain today at the 75th Annual Advertising Research Foundation conference being held at the Marriott Marquis in New York. Developed over the last three years, Mynd™ combines medical-grade technology with mobility, leapfrogging current neurological testing methods.

21 Mar 2011

Finesse launches new core modules for off-line data processing in fourth generation TruBio DV software

Finesse Solutions, LLC, a manufacturer of measurement and control solutions for life science process applications, has announced the official launch of two new core modules for off-line data processing in its fourth generation TruBio DV software. These modules are targeted at enabling bioprocessing specialists to manage data from third party equipment and process analyzers, and obtain automated electronic records of their batch.

21 Mar 2011

ACS announces definitive agreement to acquire CredenceHealth

Affiliated Computer Services, Inc. (ACS), A Xerox Company, today announced a definitive agreement to acquire CredenceHealth, Inc., creating a simple way for healthcare providers to use patient information to predict and prevent complications.

21 Mar 2011

Feihe fourth quarter revenues increased 41.6% to $62.3 million

Feihe International, Inc., one of the leading producers and distributors of premium infant formula, milk powder and soybean, rice and walnut products in China, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2010.

21 Mar 2011

Prenatal alcohol exposure another risk for conduct disorder

Alcohol use during pregnancy is common and is associated with significant threats to the health and development of exposed offspring. Despite warnings from the Surgeon General to limit alcohol use if pregnant or contemplating pregnancy, a recent survey by the National Birth Defects Prevention Study(1) found that nearly one-third of women drank alcohol at some time during their pregnancy, with one-fourth of the women surveyed having drunk during the first trimester.

21 Mar 2011

Insmed regains compliance with NASDAQ minimum bid price rule

Insmed Incorporated, a biopharmaceutical company, today announced that it has received notification from The NASDAQ Stock Market that it has regained compliance with the minimum $1.00 per share bid price requirement.

21 Mar 2011

Hi-Tech Pharmacal acquires rights to Nystatin Oral suspension ANDA from Bausch + Lomb

Hi-Tech Pharmacal Co., Inc. announced that it has acquired the rights to the Abbreviated New Drug Application (ANDA) for Nystatin Oral suspension from Bausch + Lomb, the global eye health company for an undisclosed upfront payment and a future royalty.

21 Mar 2011

Echo Therapeutics fiscal 2010 net loss decreases to $4.1 million

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the year ended December 31, 2010.

21 Mar 2011

Innovative algorithm for AEDs distinguishes betweeen adult and child arrhythmias

Ventricular Fibrillation (VF) is a series of intense and disordered contractions of the ventricles (they are located in the lower part of the heart). In 40 % of respiratory arrests suffered outside a hospital, it was shown that the first cardiac rhythm corresponds to VF, and the only manner to combat it is with electric discharges provided by defibrillation. This

21 Mar 2011

Synageva BioPharma closes $25 million private equity financing

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, announced today the closing of a $25 million private equity financing.

21 Mar 2011

Research outlines how cilia disease gene products regulate early cilium formation

An international collaboration jointly led by University College Dublin, University of Alabama and Simon Fraser University, British Columbia has outlined in the Journal of Cell Biology how cilia disease gene products regulate important aspects of early cilium formation and the integrity of the ciliary transport gate.

21 Mar 2011

FDA clears Insmed IND for ARIKACE Phase 3 clinical trial in nontuberculous mycobacteria lung infections

Insmed Incorporated, a biopharmaceutical company, announced today that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of ARIKACE™ (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung infections has been cleared by the U.S. Food and Drug Administration (FDA).

21 Mar 2011

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.

21 Mar 2011

Quest Diagnostics proposes $1,250,000,000 senior notes offering

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced today that it intends to offer $1,250,000,000 in aggregate principal amount of four series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions.

From Quest Diagnostics 21 Mar 2011

Medical News

Viewpoints: Celebrating health law anniversary (or not); Tricare's 'modest' fee increase; Funding Planned Parenthood

LTC declares $0.50 per share quarterly dividend on Series F Cumulative Preferred Stock

WaferGen, NuGEN collaborate to develop integrated workflows for gene expression profiling and target enrichment

Teleflex retires all of the 2004 senior notes

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

Anacor enters $30 million loan agreement

NeuroFocus unveils wireless headset to capture brainwave activity across the full brain

Finesse launches new core modules for off-line data processing in fourth generation TruBio DV software

ACS announces definitive agreement to acquire CredenceHealth

Feihe fourth quarter revenues increased 41.6% to $62.3 million

Prenatal alcohol exposure another risk for conduct disorder

Insmed regains compliance with NASDAQ minimum bid price rule

Hi-Tech Pharmacal acquires rights to Nystatin Oral suspension ANDA from Bausch + Lomb

Echo Therapeutics fiscal 2010 net loss decreases to $4.1 million

Innovative algorithm for AEDs distinguishes betweeen adult and child arrhythmias

Synageva BioPharma closes $25 million private equity financing

Research outlines how cilia disease gene products regulate early cilium formation

FDA clears Insmed IND for ARIKACE Phase 3 clinical trial in nontuberculous mycobacteria lung infections

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Quest Diagnostics proposes $1,250,000,000 senior notes offering

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News